Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Kun Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Haian Hospital of Traditional Chinese Medicine, Nantong, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Gastrointestinal Microbiome, Disease Models, Animal, Adalimumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Suzhou Science and Technology Planning Project in Jiangsu Province of China, Jiangsu Health Commission Medical Research Projects, China.
Abstract (Originalsprache)
Background and Aim Kui‐Jie‐Ling capsule (Kui‐Jie‐Ling) is a hospital preparation for ulcerative colitis (UC) in China. This study aimed at evaluating the protective effects and mechanisms of Kui‐Jie‐Ling and Kui‐Jie‐Ling combined with adalimumab on UC induced by dextran sulfate sodium (DSS).
Methods
Network pharmacology was combined with an animal experiment to reveal the targets of Kui‐Jie‐Ling alleviating UC. The UC model was established by drinking 2.5% DSS solution for 7 days. On the second day, the mice in the Kui‐Jie‐Ling group were orally administered with Kui‐Jie‐Ling (1.5 and 3.0 g/kg) daily for seven consecutive days, and the mice in the combination group were orally administered with Kui‐Jie‐Ling (3.0 g/kg) once a day for seven consecutive days and received one subcutaneous injection of adalimumab. The disease activity index, the colon length, the spleen index, the cytokines, the colon, the short‐chain fatty acid content, and the gut microbiota in the colon were analyzed. The role of gut microbiota against UC was verified by fecal microbiota transplantation experiments.
Results
The animal study's results were consistent with the network pharmacology analysis, which reflected that Kui‐Jie‐Ling alleviated UC via multi‐pathway. Kui‐Jie‐Ling ameliorated UC by inhibiting the formation of neutrophil extracellular traps (NETs), regulating inflammatory factors through the lipopolysaccharide–toll‐like receptor 4/nuclear factor kappa B and interleukin‐23–Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway, and restoring intestinal homeostasis.
Conclusion
These studies provided the experimental basis for the clinical administration of Kui‐Jie‐Ling and Kui‐Jie‐Ling combined with adalimumab against UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Haian Hospital of Traditional Chinese Medicine, Nantong, China.
- Suzhou Vocational Health College, Suzhou, China.
- College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
- Suzhou Institute for Food and Drug Control, Suzhou, China.
ORCID-Profile: Jian Zhang
Förderung
- National Natural Science Foundation of China
- Suzhou Science and Technology Planning Project in Jiangsu Province of China
- Jiangsu Health Commission Medical Research Projects, China
- Science and Technology Bureau of Haian City, China
- Scientific and Technological Innovation Team Building Program of Suzhou Vocational Health College
- Priority Academic Program Development of the Jiangsu Higher Education Institutes, China
- Science and Technology Planning Project of Suzhou Vocational Health College
Zitieren
APA
Li, K., Guo, L., Yu, J., Yang, Y., Wei, L., Min, C., Xu, X., Li, F., Liu, J., Zhou, G., & Zhang, J. (2024). Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16758
Vancouver
Li K, Guo L, Yu J, Yang Y, Wei L, Min C, et al. Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16758
BibTeX
@article{Li2024,
author = {Li, Kun and Guo, Lengqiu and Yu, Jinghua and Yang, Yun and Wei, Lan and Min, Chunyan and Xu, Xinkang and Li, Fang and Liu, Jiangyun and Zhou, Guangquan and Zhang, Jian},
title = {Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16758}
}
EUVIMED